Q2 EPS Estimate for Align Technology Decreased by Analyst

Align Technology, Inc. (NASDAQ:ALGN - Free Report) - Leerink Partnrs cut their Q2 2025 EPS estimates for Align Technology in a research report issued on Wednesday, April 9th. Leerink Partnrs analyst M. Cherny now anticipates that the medical equipment provider will post earnings of $1.90 per share for the quarter, down from their prior estimate of $2.09. Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Align Technology's current full-year earnings is $7.98 per share. Leerink Partnrs also issued estimates for Align Technology's Q3 2025 earnings at $1.90 EPS, Q4 2025 earnings at $2.17 EPS, FY2025 earnings at $7.46 EPS, FY2026 earnings at $8.75 EPS and FY2027 earnings at $10.20 EPS.

Align Technology (NASDAQ:ALGN - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.96 EPS for the quarter, missing analysts' consensus estimates of $2.43 by ($0.47). Align Technology had a net margin of 10.54% and a return on equity of 13.84%.

A number of other research analysts have also weighed in on ALGN. Mizuho cut their price target on shares of Align Technology from $295.00 to $250.00 and set an "outperform" rating on the stock in a research note on Tuesday, March 25th. Piper Sandler reaffirmed an "overweight" rating and issued a $235.00 target price (down from $270.00) on shares of Align Technology in a research note on Tuesday, March 18th. Morgan Stanley dropped their price target on Align Technology from $280.00 to $272.00 and set an "overweight" rating on the stock in a research note on Thursday, February 6th. Jefferies Financial Group reduced their price objective on Align Technology from $285.00 to $260.00 and set a "buy" rating for the company in a research report on Thursday, January 23rd. Finally, Leerink Partners raised Align Technology from a "market perform" rating to an "outperform" rating and lifted their target price for the company from $235.00 to $280.00 in a research report on Monday, January 6th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $256.90.

Align Technology Trading Up 2.5 %

Shares of NASDAQ ALGN traded up $4.23 during mid-day trading on Monday, reaching $171.41. 816,188 shares of the company's stock were exchanged, compared to its average volume of 875,945. Align Technology has a twelve month low of $141.74 and a twelve month high of $327.49. The firm has a market capitalization of $12.55 billion, a price-to-earnings ratio of 30.55, a PEG ratio of 2.24 and a beta of 1.73. The business has a fifty day simple moving average of $172.70 and a 200 day simple moving average of $204.78.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Norges Bank bought a new position in Align Technology during the fourth quarter worth about $190,792,000. Meridiem Investment Management Ltd. boosted its stake in shares of Align Technology by 63.7% during the 4th quarter. Meridiem Investment Management Ltd. now owns 764,732 shares of the medical equipment provider's stock worth $159,470,000 after acquiring an additional 297,472 shares during the period. Senvest Management LLC boosted its stake in shares of Align Technology by 58.1% during the 4th quarter. Senvest Management LLC now owns 726,243 shares of the medical equipment provider's stock worth $151,429,000 after acquiring an additional 267,000 shares during the period. Resona Asset Management Co. Ltd. bought a new stake in Align Technology in the 4th quarter valued at $47,853,000. Finally, Raymond James Financial Inc. bought a new stake in Align Technology in the 4th quarter valued at $42,243,000. 88.43% of the stock is currently owned by institutional investors and hedge funds.

About Align Technology

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.